Semi-permeable coatings fabricated from comb-polymers efficiently protect proteins in vivo

Nature Communications

Volumn 5, Issue , 2014, Pages

  Liu, Mi ^a   Johansen, Pål ^b   Zabel, Franziska ^b   Leroux, Jean Christophe ^a   Gauthier, Marc A ^a,c  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c INRS EMT   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; EPITOPE; POLYMER; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; METHACRYLIC ACID DERIVATIVE; POLYETHYLENE GLYCOL METHACRYLATE;

BIOACTIVITY; COATING; COMPLEXATION; PARAMETERIZATION; PERMEABILITY; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MICROTECHNOLOGY; MOUSE; NONHUMAN; PERMEABILITY; PROTEIN MODIFICATION; ANIMAL; CHEMISTRY; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; DRUG CARRIERS; METHACRYLATES; MICE; PERMEABILITY; POLYETHYLENE GLYCOLS;

EID: 84923345372     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6526     Document Type: Article

References (47)

1. Harris, J. M. & Chess, R. B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-221 (2003).
2. Pasut, G. & Veronese, F. M. State of the art in PEGylation: The great versatility achieved after forty years of research. J. Control. Release 161, 461-472 (2012).
3. Alconcel, S. N. S., Baas, A. S. & Maynard, H. D. FDA-Approved poly(ethylene glycol)-protein conjugate drugs. Polym. Chem. 2, 1442-1448 (2011).
4. Duncan, R. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347-360 (2003).
5. Matyjaszewski, K. & Tsarevsky, N. V. Nanostructured functional materials prepared by atom transfer radical polymerization. Nat. Chem. 1, 276-288 (2009).
6. Schmidt BVKJ, Fechler N, Falkenhagen, J. & Lutz, J.-F. Controlled folding of synthetic polymer chains through the formation of positionable covalent bridges. Nat. Chem. 3, 234-238 (2011).
7. Kissel, P. et al. A two-dimensional polymer prepared by organic synthesis. Nat. Chem. 4, 287-291 (2012).
8. Nguyen, T. H. et al. A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor. Nat. Chem. 5, 221-227 (2013).
9. Keefe, A. J. & Jiang, S. Poly(zwitterionic)protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nat. Chem. 4, 59-63 (2012).
10. Fuhrmann, G. et al. Sustained gastrointestinal activity of dendronized polymer-enzyme conjugates. Nat. Chem. 5, 582-589 (2013).
11. Fuhrmann, G. & Leroux, J.-C. In vivo fluorescence imaging of exogenous enzyme activity in the gastrointestinal tract. Proc. Natl Acad. Sci. USA 108, 9032-9037 (2011).
12. Liu, M. et al. Molecular Sieving on the Surface of a Protein Provides Protection Without Loss of Activity. Adv. Funct. Mater. 23, 2007-2015 (2013).
13. Fu, C. H. & Sakamoto, K. M. PEG-Asparaginase. Expert Opin. Pharmacother. 8, 1977-1984 (2007).
14. Müller, H.-J. et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br. J. Haematol. 114, 794-799 (2001).
15. Hak, L. J. et al. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Leukemia 18, 1072-1077 (2004).
16. Avramis, V. I. et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99, 1986-1994 (2002).
17. Asselin, B. L. et al. Comparative pharmacokinetic studies of three asparaginase preparations. J. Clin. Oncol. 11, 1780-1786 (1993).
18. Salzer, W. L. et al. Intensified PEG-L-Asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a Report From the Children's Oncology Group. J. Pediatr. Hematol. Oncol. 29, 369-375 (2007).
19. Schrey, D. et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr. Blood Cancer 54, 952-958 (2010).
20. Murthy, N. S. & Knox, J. R. Small-Angle X-ray scattering studies of Escherichia coli l-Asparaginase. J. Mol. Biol. 105, 567-575 (1976).
21. Lucon, J. et al. Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading. Nat. Chem. 4, 781-788 (2012).
22. Lele, B. S., Murata, H., Matyjaszewski, K. & Russell, A. J. Synthesis of Uniform Protein-Polymer Conjugates. Biomacromolecules 6, 3380-3387 (2005).
23. Cummings, C., Murata, H., Koepsel, R. & Russell, A. J. Tailoring enzyme activity and stability using polymer-based protein engineering. Biomaterials 34, 7437-7443 (2013).
24. Murata, H., Cummings, C. S., Koepsel, R. R. & Russell, A. J. Polymer-Based Protein Engineering Can Rationally Tune Enzyme Activity, pH-Dependence, and Stability. Biomacromolecules 14, 1919-1926 (2013).
25. Cummings, C., Murata, H., Koepsel, R. & Russell, A. J. Dramatically increased pH and temperature stability of chymotrypsin using dual block polymer-based protein engineering. Biomacromolecules 15, 763-771 (2014).
26. Cheng, G. et al. Small angle neutron scattering study of conformation of oligo(ethylene glycol)-grafted polystyrene in dilute solutions: effect of the backbone length. Macromolecules 41, 9831-9836 (2008).
27. Roth, P. J., Davis, T. P. & Lowe, A. B. Comparison between the LCST and UCST transitions of double thermoresponsive diblock copolymers: insights into the behavior of POEGMA in alcohols. Macromolecules 45, 3221-3230 (2012).
28. Ho, D. H. et al. Polyethylene glycol-L-Asparaginase and L-Asparaginase studies in rabbits. Drug Metab. Dispos. 16, 27-29 (1988).
29. Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G. & Richette, P. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin. Drug Deliv. 9, 1319-1323 (2012).
30. Armstrong, J. K. et al. Antibody against poly(ethylene glycol) adversely affects PEG-Asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110, 103-111 (2007).
31. Gauthier, M. A. & Klok, H.-A. Polymer-protein conjugates: an enzymatic activity perspective. Polym. Chem. 1, 1352-1373 (2010).
32. Pasut, G., Sergi, M. & Veronese, F. M. Anti-cancer PEG-enzymes: 30 years old, but still a current approach. Adv. Drug Deliv. Rev. 60, 69-78 (2008).
33. Veronese, F. M. et al. Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol). J. Control. Release 40, 199-209 (1996).
34. Monfardini, C. et al. A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug. Chem. 6, 62-69 (1995).
35. Ma, H., Wells, M., Beebe, T. P. & Chilkoti, A. Surface-initiated atom transfer radical polymerization of oligo(ethylene glycol) methyl methacrylate from a mixed self-Assembled monolayer on gold. Adv. Funct. Mater. 16, 640-648 (2006).
36. Ma, H., Hyun, J., Stiller, P. & Chilkoti, A. 'Non-fouling' oligo(ethylene glycol)-functionalized polymer brushes synthesized by surface-initiated atom transfer radical polymerization. Adv. Mater. 16, 338-341 (2004).
37. Magnusson, J. P., Bersani, S., Salmaso, S., Alexander, C. & Caliceti, P. In situ growth of side-chain peg polymers from functionalized human growth hormone-A new technique for preparation of enhanced protein-polymer conjugates. Bioconjug. Chem. 21, 671-678 (2010).
38. Gao, W. P., Liu, W. G., Christensen, T., Zalutsky, M. R. & Chilkoti, A. In situ growth of a PEG-like polymer from the C terminus of an intein fusion protein improves pharmacokinetics and tumor accumulation. Proc. Natl Acad. Sci. USA 107, 16432-16437 (2010).
39. Gao, W. P. et al. In situ growth of a stoichiometric PEG-like conjugate at a protein's N-terminus with significantly improved pharmacokinetics. Proc. Natl Acad. Sci. USA 106, 15231-15236 (2009).
40. Ryan, S. M. et al. Conjugation of salmon calcitonin to a combed-shaped end functionalized poly(poly(ethylene glycol) methyl ether methacrylate) yields a bioactive stable conjugate. J. Control. Release 135, 51-59 (2009).
41. Werner, A., Röhm, K.-H. & Müller, H.-J. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment. In: Biol. Chem. 386, 535-540 (2005).
42. Patel, N. et al. A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-Asparaginase. J. Clin. Invest. 119, 1964-1973 (2009).
43. Shaunak, S. et al. Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat. Chem. Biol. 2, 312-313 (2006).
44. Balan, S. et al. Site-specific PEGylation of protein disulfide bonds using a threecarbon bridge. Bioconjug. Chem. 18, 61-76 (2006).
45. Tinberg, C. E. et al. Computational design of ligand-binding proteins with high affinity and selectivity. Nature 501, 212-216 (2013).
46. Jayaram, H. N., Cooney, D. A., Jayaram, S. & Rosenblu, L. Simple and rapid method for estimation of L-Asparaginase in chromatographic and electrophoretic effluents-comparison with other methods. Anal. Biochem. 59, 327-346 (1974).
47. Bidlingmeyer, B. A., Cohen, S. A. & Tarvin, T. L. Rapid analysis of amino-Acids using pre-column derivatization. J. Chromatogr. 336, 93-104 (1984).